Genetic susceptibility to adverse drug reactions (Q34275394)

1 August 2017

1 reference

title

Genetic susceptibility to adverse drug reactions (English)

1 reference

1 August 2017

Pirmohamed M

1

1 reference

1 August 2017

Park BK

series ordinal

2

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Trends in Pharmacological Sciences

1 August 2017

published in

1 reference

1 August 2017

volume

22

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

298-305

1 reference

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Drug-related hospital admissions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

New active substances authorized in the United Kingdom between 1972 and 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Getting the right drug into the right patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Adverse drug reactions: definitions, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Pharmacogenetics and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Association of CYP3A4 genotype with treatment-related leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

1 reference

7 January 2021

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Toxicogenetics in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Prevention of stroke in patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Cytochrome P450 polymorphisms are associated with reduced warfarin dose

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Human P450 metabolism of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Warfarin usage: can safety be improved?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Idiosyncratic drug reactions: a mechanistic evaluation of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

1 reference

7 January 2021

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Pharmacogenetics: a tool for individualizing antineoplastic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Glutathione S‐transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

The purine path to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Pharmacogenetics of cancer therapy: getting personal

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

High incidence of secondary brain tumours after radiotherapy and antimetabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Glucose-6-phosphate dehydrogenase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Pharmacogenomics of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Ryanodine receptor mutations in malignant hyperthermia and central core disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Pharmacogenetics of cardiac K(+) channels

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

A common polymorphism associated with antibiotic-induced cardiac arrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Idiosyncratic drug reactions: the reactive metabolite syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Single nucleotide polymorphisms as tools in human genetics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Genetic predisposition to phenytoin-induced birth defects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Interpretation of results from genetic studies of multifactorial diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Pharmacogenetics and the practice of medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Pharmacogenetics in the new patterns of healthcare delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

Testing drug response in the presence of genetic information: sampling issues for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901717-X

7 January 2021

10.1016/S0165-6147(00)01717-X

Identifiers

DOI

1 reference

1 August 2017

1 reference